Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3

Figure 5

miR-26b abrogates the doxorubicin-activated NF-κB signaling. (A) Expression of miR-26b reduced the doxorubicin-induced NF-κB reporter activity. HCC cells were first transfected with NC or miR-26b duplexes, followed by co-transfection of pRL-TK and pNF-κB-Luc or pTAL-Luc, then remained untreated (Ctrl) or treated (DOX) with doxorubicin before luciferase activity analysis. (B) Introduction of miR-26b attenuated the doxorubicin-triggered phosphorylation of IκBα and p65. HCC cells transfected with NC or miR-26b were untreated (-) or treated (+) with doxorubicin for 6 hours before immunoblotting. (C) miR-26b suppressed the doxorubicin-induced expression of NF-κB target genes. QGY-7703 cells transfected with NC or miR-26b duplexes were untreated (Ctrl) or treated (DOX) with doxorubicin for 24 hours before qPCR analysis. (D) Knockdown of TAK1 or TAB3 suppressed the doxorubicin-stimulated NF-κB reporter activity. QGY-7703 cells were first transfected with the indicated siRNA duplexes, followed by treatment and analysis as in Figure 5A. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Back to article page

Molecular Cancer

ISSN: 1476-4598